Cargando…
Development of orthotopic tumour models using ultrasound-guided intrahepatic injection
Mouse models of human diseases are an essential part of the translational pipeline. Orthotopic tumour mouse models are increasingly being used in cancer research due to their increased clinical relevance over subcutaneous xenograft models, particularly in relation to metastatic disease. In this stud...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616610/ https://www.ncbi.nlm.nih.gov/pubmed/31289364 http://dx.doi.org/10.1038/s41598-019-46410-6 |
_version_ | 1783433544753741824 |
---|---|
author | McVeigh, L. E. Wijetunga, I. Ingram, N. Marston, G. Prasad, R. Markham, A. F. Coletta, P. L. |
author_facet | McVeigh, L. E. Wijetunga, I. Ingram, N. Marston, G. Prasad, R. Markham, A. F. Coletta, P. L. |
author_sort | McVeigh, L. E. |
collection | PubMed |
description | Mouse models of human diseases are an essential part of the translational pipeline. Orthotopic tumour mouse models are increasingly being used in cancer research due to their increased clinical relevance over subcutaneous xenograft models, particularly in relation to metastatic disease. In this study, we have developed orthotopic colorectal cancer liver metastases (CRCLM) and primary cholangiocarcinoma (CCA) models in BALB/c nude mice using minimally invasive ultrasound-guided intrahepatic injection. Due to its minimally invasive nature, the method reduced risk from surgical complications whilst being fast and easy to perform and resulted in measurable tumour volumes 1 to 3 weeks post-injection. Tumour volumes were monitored in vivo by weekly high-frequency ultrasound (HF-US) and/or twice weekly bioluminescence imaging (BLI) and confirmed with end-point histology. Take rates were high for human CRC cells (>73%) and for CCA cells (90%). We have demonstrated that this method reliably induces CRCLM and CCAs, in which tumour volume can be monitored throughout using HF-US and/or BLI. This provides a promising experimental tool for future testing of cancer therapeutics in an orthotopic model. |
format | Online Article Text |
id | pubmed-6616610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-66166102019-07-18 Development of orthotopic tumour models using ultrasound-guided intrahepatic injection McVeigh, L. E. Wijetunga, I. Ingram, N. Marston, G. Prasad, R. Markham, A. F. Coletta, P. L. Sci Rep Article Mouse models of human diseases are an essential part of the translational pipeline. Orthotopic tumour mouse models are increasingly being used in cancer research due to their increased clinical relevance over subcutaneous xenograft models, particularly in relation to metastatic disease. In this study, we have developed orthotopic colorectal cancer liver metastases (CRCLM) and primary cholangiocarcinoma (CCA) models in BALB/c nude mice using minimally invasive ultrasound-guided intrahepatic injection. Due to its minimally invasive nature, the method reduced risk from surgical complications whilst being fast and easy to perform and resulted in measurable tumour volumes 1 to 3 weeks post-injection. Tumour volumes were monitored in vivo by weekly high-frequency ultrasound (HF-US) and/or twice weekly bioluminescence imaging (BLI) and confirmed with end-point histology. Take rates were high for human CRC cells (>73%) and for CCA cells (90%). We have demonstrated that this method reliably induces CRCLM and CCAs, in which tumour volume can be monitored throughout using HF-US and/or BLI. This provides a promising experimental tool for future testing of cancer therapeutics in an orthotopic model. Nature Publishing Group UK 2019-07-09 /pmc/articles/PMC6616610/ /pubmed/31289364 http://dx.doi.org/10.1038/s41598-019-46410-6 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article McVeigh, L. E. Wijetunga, I. Ingram, N. Marston, G. Prasad, R. Markham, A. F. Coletta, P. L. Development of orthotopic tumour models using ultrasound-guided intrahepatic injection |
title | Development of orthotopic tumour models using ultrasound-guided intrahepatic injection |
title_full | Development of orthotopic tumour models using ultrasound-guided intrahepatic injection |
title_fullStr | Development of orthotopic tumour models using ultrasound-guided intrahepatic injection |
title_full_unstemmed | Development of orthotopic tumour models using ultrasound-guided intrahepatic injection |
title_short | Development of orthotopic tumour models using ultrasound-guided intrahepatic injection |
title_sort | development of orthotopic tumour models using ultrasound-guided intrahepatic injection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616610/ https://www.ncbi.nlm.nih.gov/pubmed/31289364 http://dx.doi.org/10.1038/s41598-019-46410-6 |
work_keys_str_mv | AT mcveighle developmentoforthotopictumourmodelsusingultrasoundguidedintrahepaticinjection AT wijetungai developmentoforthotopictumourmodelsusingultrasoundguidedintrahepaticinjection AT ingramn developmentoforthotopictumourmodelsusingultrasoundguidedintrahepaticinjection AT marstong developmentoforthotopictumourmodelsusingultrasoundguidedintrahepaticinjection AT prasadr developmentoforthotopictumourmodelsusingultrasoundguidedintrahepaticinjection AT markhamaf developmentoforthotopictumourmodelsusingultrasoundguidedintrahepaticinjection AT colettapl developmentoforthotopictumourmodelsusingultrasoundguidedintrahepaticinjection |